Literature DB >> 11331615

Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release.

N R Jana1, E A Zemskov, N Nukina.   

Abstract

Expansion of CAG repeats within the coding region of target genes is the cause of several autosomal dominant neurodegenerative diseases including Huntington's disease (HD). A hallmark of HD is the proteolytic production of N-terminal fragments of huntingtin containing polyglutamine repeats that form ubiquitinated aggregates in the nucleus and cytoplasm of the affected neurons. In this study, we used an ecdysone-inducible stable mouse neuro2a cell line that expresses truncated N-terminal huntingtin (tNhtt) with different polyglutamine length, along with mice transgenic for HD exon 1, to demonstrate that the ubiquitin-proteasome pathway is involved in the pathogenesis of HD. Proteasomal 20S core catalytic component was redistributed to the polyglutamine aggregates in both the cellular and transgenic mouse models. Proteasome inhibitor dramatically increased the rate of aggregate formation caused by tNhtt protein with 60 glutamine (60Q) repeats, but had very little influence on aggregate formation by tNhtt protein with 150Q repeats. Both normal and polyglutamine-expanded tNhtt proteins were degraded by proteasome, but the rate of degradation was inversely proportional to the repeat length. The shift of the proteasomal components from the total cellular environment to the aggregates, as well as the comparatively slower degradation of tNhtt with longer polyglutamine, decreased the proteasome's availability for degrading other key target proteins, such as p53. This altered proteasomal function was associated with disrupted mitochondrial membrane potential, released cytochrome c from mitochondria into the cytosol and activated caspase-9- and caspase-3-like proteases. These results suggest that the impaired proteasomal function plays an important role in polyglutamine protein-induced cell death.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11331615     DOI: 10.1093/hmg/10.10.1049

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  130 in total

Review 1.  Huntington's disease.

Authors:  S Davies; D B Ramsden
Journal:  Mol Pathol       Date:  2001-12

2.  Proteasomal-dependent aggregate reversal and absence of cell death in a conditional mouse model of Huntington's disease.

Authors:  E Martín-Aparicio; A Yamamoto; F Hernández; R Hen; J Avila; J J Lucas
Journal:  J Neurosci       Date:  2001-11-15       Impact factor: 6.167

3.  Mutant huntingtin-impaired degradation of beta-catenin causes neurotoxicity in Huntington's disease.

Authors:  Juliette D Godin; Ghislaine Poizat; Miriam A Hickey; Florence Maschat; Sandrine Humbert
Journal:  EMBO J       Date:  2010-06-08       Impact factor: 11.598

Review 4.  Modifiers and mechanisms of multi-system polyglutamine neurodegenerative disorders: lessons from fly models.

Authors:  Moushami Mallik; Subhash C Lakhotia
Journal:  J Genet       Date:  2010-12       Impact factor: 1.166

5.  Targeting expression of expanded polyglutamine proteins to the endoplasmic reticulum or mitochondria prevents their aggregation.

Authors:  Erwann Rousseau; Benjamin Dehay; Léa Ben-Haïem; Yvon Trottier; Michel Morange; Anne Bertolotti
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-21       Impact factor: 11.205

6.  Inefficient degradation of truncated polyglutamine proteins by the proteasome.

Authors:  Carina I Holmberg; Kristine E Staniszewski; Kwame N Mensah; Andreas Matouschek; Richard I Morimoto
Journal:  EMBO J       Date:  2004-10-07       Impact factor: 11.598

7.  Huntington's disease and mitochondrial alterations: emphasis on experimental models.

Authors:  Verónica Pérez-De la Cruz; Paul Carrillo-Mora; Abel Santamaría
Journal:  J Bioenerg Biomembr       Date:  2010-06       Impact factor: 2.945

8.  Neuronal induction of the immunoproteasome in Huntington's disease.

Authors:  Miguel Díaz-Hernández; Félix Hernández; Ester Martín-Aparicio; Pilar Gómez-Ramos; María A Morán; José G Castaño; Isidro Ferrer; Jesús Avila; José J Lucas
Journal:  J Neurosci       Date:  2003-12-17       Impact factor: 6.167

9.  Genetic evidence linking age-dependent attenuation of the 26S proteasome with the aging process.

Authors:  Ayako Tonoki; Erina Kuranaga; Takeyasu Tomioka; Jun Hamazaki; Shigeo Murata; Keiji Tanaka; Masayuki Miura
Journal:  Mol Cell Biol       Date:  2008-12-15       Impact factor: 4.272

Review 10.  The ubiquitin-proteasome pathway in Huntington's disease.

Authors:  Steven Finkbeiner; Siddhartha Mitra
Journal:  ScientificWorldJournal       Date:  2008-04-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.